BR9811558A - Terapêutica combinada compreendendo um composto amlodipina e uma estatina - Google Patents

Terapêutica combinada compreendendo um composto amlodipina e uma estatina

Info

Publication number
BR9811558A
BR9811558A BR9811558-8A BR9811558A BR9811558A BR 9811558 A BR9811558 A BR 9811558A BR 9811558 A BR9811558 A BR 9811558A BR 9811558 A BR9811558 A BR 9811558A
Authority
BR
Brazil
Prior art keywords
combinations
pharmaceutically acceptable
amlodipine
statin
combined
Prior art date
Application number
BR9811558-8A
Other languages
English (en)
Inventor
Jan Buch
Robert Andrew Donald Scott
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22011309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9811558(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR9811558A publication Critical patent/BR9811558A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Patente de Invenção: <B>"TERAPêUTICA COMBINADA COMPREENDENDO UM COMPOSTO AMLODIPINA E UMA ESTATINA"<D>. Esta invenção refere-se a combinações farmacêuticas de amlodipina ou um seu sal de adição de ácido farmaceuticamente aceitável e estatinas ou seus sais farmaceuticamente aceitáveis, kits contendo essas combinações e métodos para a utilização dessas combinações para tratar indivíduos que sofrem de angina de peito, aterosclerose, hipertensão e hiperlipidemia combinadas e para tratar indivíduos apresentando sintomas de risco cardíaco, incluindo seres humanos. Esta invenção também refere-se a combinações aditivas e sinergísticas de amlodipina ou um seu sal de adição de ácido farmaceuticamente aceitável e estatinas ou seus sais farmaceuticamente aceitáveis em que essas combinações aditivas e sinergísticas são úteis para o tratamento de indivíduos que sofrem de angina de peito, aterosclerose, hipertensão e hiperlipidemia combinadas e os indivíduos que apresentam sintomas de risco cardíaco, incluindo seres humanos.
BR9811558-8A 1997-08-29 1998-08-10 Terapêutica combinada compreendendo um composto amlodipina e uma estatina BR9811558A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5755597P 1997-08-29 1997-08-29
PCT/IB1998/001220 WO1999011263A1 (en) 1997-08-29 1998-08-10 Combination therapy comprising amlodipine and a statin compound

Publications (1)

Publication Number Publication Date
BR9811558A true BR9811558A (pt) 2000-08-22

Family

ID=22011309

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811558-8A BR9811558A (pt) 1997-08-29 1998-08-10 Terapêutica combinada compreendendo um composto amlodipina e uma estatina

Country Status (36)

Country Link
US (1) US20020025981A1 (pt)
EP (1) EP1003507A1 (pt)
JP (1) JP2001514224A (pt)
KR (1) KR20010022385A (pt)
CN (1) CN1117566C (pt)
AP (1) AP1207A (pt)
AR (1) AR017514A1 (pt)
AU (1) AU744982B2 (pt)
BG (1) BG104076A (pt)
BR (1) BR9811558A (pt)
CA (1) CA2296726C (pt)
CO (1) CO4970726A1 (pt)
DZ (1) DZ2600A1 (pt)
EA (1) EA002705B1 (pt)
GT (1) GT199800134A (pt)
HN (1) HN1998000124A (pt)
HR (1) HRP980475A2 (pt)
HU (1) HUP0003103A3 (pt)
ID (1) ID24275A (pt)
IL (2) IL133957A0 (pt)
IS (1) IS5345A (pt)
MA (1) MA26539A1 (pt)
NO (1) NO20000999D0 (pt)
NZ (1) NZ502283A (pt)
OA (1) OA11289A (pt)
PA (1) PA8457201A1 (pt)
PE (1) PE106999A1 (pt)
PL (1) PL339088A1 (pt)
SA (1) SA98190432A (pt)
SK (1) SK1392000A3 (pt)
TN (1) TNSN98158A1 (pt)
TR (1) TR200000562T2 (pt)
UY (1) UY25159A1 (pt)
WO (1) WO1999011263A1 (pt)
YU (1) YU2700A (pt)
ZA (1) ZA987843B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07506822A (ja) 1992-05-19 1995-07-27 ノボゲン　リサーチ　ピーティーワイ　リミッテッド フィト−エストロゲン，類似体またはその代謝産物を含有する健康補助剤
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
AU3103800A (en) 1998-12-23 2000-07-31 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acidderivatives for cardiovascular indications
EP1076091A1 (en) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
AUPQ266199A0 (en) 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
EP1314425A4 (en) * 2000-08-30 2004-06-02 Sankyo Co MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
AUPR363301A0 (en) 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
MXPA04006255A (es) 2002-01-17 2004-09-27 Pharmacia Corp Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005097191A2 (en) * 2004-04-04 2005-10-20 Sepracor Inc. COMBINATIONS COMPRISING (S)- AMLODIPINE AND A HMG-CoA REDUCTASE INHIBITOR OR CHOLESTEROL ABSORPOTION INHIBITOR OR BOTH, AND METHODS FOR REDUCING HYPERTENSION
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR100742432B1 (ko) * 2005-12-27 2007-07-24 한미약품 주식회사 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
WO2007111027A1 (ja) * 2006-03-29 2007-10-04 Kowa Co., Ltd. トリグリセリド低下剤及び高インスリン血症改善剤
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023958A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
MX2007008440A (es) * 2007-07-11 2009-02-18 Senosiain S A De C V Lab Composicion farmaceutica combinada.
KR101207618B1 (ko) * 2008-02-22 2012-12-04 한올바이오파마주식회사 심혈관계 질환 치료용 약제학적 제제
WO2009125987A2 (ko) * 2008-04-10 2009-10-15 한올제약주식회사 약제학적 제제
WO2010008203A2 (ko) * 2008-07-15 2010-01-21 한올제약주식회사 칼슘채널길항제를 포함하는 약제학적 제제
CN101804055B (zh) * 2010-04-27 2012-01-25 施慧达药业集团(吉林)有限公司 复方药物制剂
US20190263888A1 (en) 2010-10-19 2019-08-29 Op-T Llc Therapeutic peptides and methods for treating autoimmune related disease
EP2629797B1 (en) 2010-10-19 2018-05-23 The Regents of the University of Colorado, A Body Corporate Peptides for modulating t-cell activity and uses thereof
ES2905872T3 (es) 2015-02-06 2022-04-12 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia combinada
WO2019094581A1 (en) * 2017-11-10 2019-05-16 Op-T Llc Methods for preventing, modulating and/or reducing cardiovascular disease
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
WO2021108343A1 (en) * 2019-11-25 2021-06-03 Fordoz Pharma C0Rp. Formulations comprising lipid-lowering and blood pressure-lowering drugs
US12048734B2 (en) 2020-04-17 2024-07-30 Op-T Llc Bioactive peptides and methods of use thereof
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN176897B (pt) * 1993-10-29 1996-09-28 Cadila Lab Ltd
DE19539363A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von festen Arzneiformen

Also Published As

Publication number Publication date
SK1392000A3 (en) 2000-08-14
TNSN98158A1 (fr) 2005-03-15
UY25159A1 (es) 2000-12-29
ID24275A (id) 2000-07-13
IL133957A0 (en) 2001-04-30
OA11289A (en) 2003-08-25
PE106999A1 (es) 1999-11-06
NO20000999L (no) 2000-02-28
CN1117566C (zh) 2003-08-13
HRP980475A2 (en) 1999-06-30
HUP0003103A2 (hu) 2001-01-29
AR017514A1 (es) 2001-09-12
HK1029530A1 (en) 2001-04-06
JP2001514224A (ja) 2001-09-11
IS5345A (is) 2000-01-14
SA98190432A (ar) 2005-12-03
AP1207A (en) 2003-09-20
AP9801333A0 (en) 1998-09-30
PL339088A1 (en) 2000-12-04
HUP0003103A3 (en) 2002-03-28
EA200000013A1 (ru) 2000-08-28
US20020025981A1 (en) 2002-02-28
ZA987843B (en) 2000-02-28
CO4970726A1 (es) 2000-11-07
TR200000562T2 (tr) 2000-08-21
DZ2600A1 (fr) 2003-03-01
NZ502283A (en) 2002-05-31
EP1003507A1 (en) 2000-05-31
CA2296726A1 (en) 1999-03-11
CN1268054A (zh) 2000-09-27
KR20010022385A (ko) 2001-03-15
PA8457201A1 (es) 2000-05-24
AU8458598A (en) 1999-03-22
YU2700A (sh) 2002-06-19
IL133957A (en) 2006-06-11
CA2296726C (en) 2004-06-29
HN1998000124A (es) 1999-02-09
GT199800134A (es) 2000-02-08
WO1999011263A1 (en) 1999-03-11
BG104076A (en) 2000-09-29
MA26539A1 (fr) 2004-12-20
NO20000999D0 (no) 2000-02-28
EA002705B1 (ru) 2002-08-29
AU744982B2 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
BR9812030A (pt) Combinações terapêuticas compreendendo amlodipina e atorvastatina
BR9811556A (pt) Terapia de combinação compreendendo atorvastatina e um agente anti-hipertensivo
EA200000013A1 (ru) Комбинационная терапия, включающая в себя амлодипин и статиновое соединение
EA200300155A1 (ru) Терапевтическая комбинация ингибитора сетр и аторвастатина
BRPI0517481A (pt) método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica
EA200101132A1 (ru) Взаимная соль амлодипина и аторвастатина
PT705100E (pt) Guanidinas substituidas terapeuticas
BR9900653A (pt) Método para tratamento da insuficiência cardìaca
NO954878L (no) Pyrrolderivater
BRPI0410049A (pt) composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, uso de um composto, composição farmacêutica, e, kit farmacêutico
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BR9812660A (pt) Composições e métodos para tratar distúrbios respiratórios
BR9916432A (pt) Compostos de triazinona para o tratamento de doenças devido ao sarcosystis, neospora e ao toxoplasma
BR9712307A (pt) Pirazolinonas para o tratamento de potência enfraquecida
BR9814867A (pt) Método para tratar discinesias relacionadas a doenças ou induzidas por drogas
ECSP982645A (es) Terapia de combinacion
ECSP982646A (es) Combinaciones terapeuticas
UY27510A1 (es) Terapia de combinación

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]